ClariTrial | Search Clinical Trials

Explore/cancer oncology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

6,266 results for “cancer oncology” · Recruiting · Phase 3 · Phase 2

Page 1 of 418

Recruiting

Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma

Phase 2Unresectable Melanoma

Prebiotic Food-Enriched Diet

M.D. Anderson Cancer Center75 participants1 site · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)

Phase 2Sarcoma,Soft Tissue

Selinexor 20 MGGemcitabine

Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas88 participants11 sites · SpainCompletes May 2026

Compare CT.gov Full analysis →

Recruiting

DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer

Phase 3Older PatientsColorectal CancerMetastatic Cancer

Doublet Chemotherapy, Standard Dose (100%)Doublet Chemotherapy, Dose-reduced (75%)Monotherapy, Standard Dose (100%)+1 more

Leiden University Medical Center587 participants36 sites · NetherlandsCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors

Phase 3Germ Cell Tumor

Thromboprophylaxis

Gustave Roussy, Cancer Campus, Grand Paris387 participants26 sites · FranceCompletes Feb 2028

Compare CT.gov Full analysis →

Recruiting

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Phase 2T-cell Acute Lymphoblastic Leukemia

Daratumumab / Hyaluronidase InjectionDaratumumab / Hyaluronidase InjectionDaratumumab / Hyaluronidase Injection+1 more

Eastern Cooperative Oncology Group20 participants1 site · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)

Phase 2Colorectal Cancer Liver Metastases (CRLM)

AK104 with radiotherapyStandard of therapy

Fudan University73 participants1 site · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS

Phase 3Gastric Cancer

capecitabine

Asan Medical Center870 participants1 site · South KoreaCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Dose Escalation For INtraprostatic LEsions

Phase 2Prostatic Neoplasms

Prostate SBRT with Focal BoostTriptorelin Injection

Ottawa Hospital Research Institute54 participants1 site · CanadaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

Phase 2Female, Age ≥ 18 Years OldNo Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/ImmunotherapyECOG Score of 0-1

Cadonilimab combined with cisplatin

The First Affiliated Hospital of Zhengzhou University29 participants1 site · ChinaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors

Phase 1Phase 2Solid Tumors

RC278

RemeGen Co., Ltd.312 participants39 sites · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Phase 2Pancreatic AdenocarcinomaAmpulla of Vater CarcinomaAdrenocortical Carcinoma

DostarlimabChemotherapy

UNICANCER120 participants22 sites · FranceCompletes Oct 2028

Compare CT.gov Full analysis →

Recruiting

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Phase 2Phase 3Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Biospecimen CollectionCemiplimabComputed Tomography+4 more

SWOG Cancer Research Network378 participants361 sites · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy

Phase 3Cervical Cancer

No adjuvant therapyAdjuvant radiotherapy

The Central and Eastern European Gynecologic Oncology Group514 participants1 site · CzechiaCompletes Dec 2029

Compare CT.gov Full analysis →

Recruiting

D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC

Phase 3NSCLC (Non-small Cell Lung Cancer)

D-BACE in combination with chemotherapy and karelizumab

Guangdong Provincial People's Hospital70 participants1 site · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Phase 1Phase 2Locally Advanced Breast CancerUnresectable Breast CarcinomaMetastatic Breast Cancer

BNT323BNT327

BioNTech SE380 participants39 sites · United States, Canada, ChinaCompletes May 2028

Compare CT.gov Full analysis →

1–15 of 6,266

Explore/cancer oncology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

6,266 results for “cancer oncology” · Recruiting · Phase 3 · Phase 2

Page 1 of 418

Recruiting

Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma

Phase 2Unresectable Melanoma

Prebiotic Food-Enriched Diet

M.D. Anderson Cancer Center75 participants1 site · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)

Phase 2Sarcoma,Soft Tissue

Selinexor 20 MGGemcitabine

Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas88 participants11 sites · SpainCompletes May 2026

Compare CT.gov Full analysis →

Recruiting

DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer

Phase 3Older PatientsColorectal CancerMetastatic Cancer

Doublet Chemotherapy, Standard Dose (100%)Doublet Chemotherapy, Dose-reduced (75%)Monotherapy, Standard Dose (100%)+1 more

Leiden University Medical Center587 participants36 sites · NetherlandsCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors

Phase 3Germ Cell Tumor

Thromboprophylaxis

Gustave Roussy, Cancer Campus, Grand Paris387 participants26 sites · FranceCompletes Feb 2028

Compare CT.gov Full analysis →

Recruiting

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Phase 2T-cell Acute Lymphoblastic Leukemia

Daratumumab / Hyaluronidase InjectionDaratumumab / Hyaluronidase InjectionDaratumumab / Hyaluronidase Injection+1 more

Eastern Cooperative Oncology Group20 participants1 site · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)

Phase 2Colorectal Cancer Liver Metastases (CRLM)

AK104 with radiotherapyStandard of therapy

Fudan University73 participants1 site · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS

Phase 3Gastric Cancer

capecitabine

Asan Medical Center870 participants1 site · South KoreaCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Dose Escalation For INtraprostatic LEsions

Phase 2Prostatic Neoplasms

Prostate SBRT with Focal BoostTriptorelin Injection

Ottawa Hospital Research Institute54 participants1 site · CanadaCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer

Phase 2Female, Age ≥ 18 Years OldNo Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/ImmunotherapyECOG Score of 0-1

Cadonilimab combined with cisplatin

The First Affiliated Hospital of Zhengzhou University29 participants1 site · ChinaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors

Phase 1Phase 2Solid Tumors

RC278

RemeGen Co., Ltd.312 participants39 sites · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Phase 2Pancreatic AdenocarcinomaAmpulla of Vater CarcinomaAdrenocortical Carcinoma

DostarlimabChemotherapy

UNICANCER120 participants22 sites · FranceCompletes Oct 2028

Compare CT.gov Full analysis →

Recruiting

Phase 2Phase 3Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Biospecimen CollectionCemiplimabComputed Tomography+4 more

SWOG Cancer Research Network378 participants361 sites · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy

Phase 3Cervical Cancer

No adjuvant therapyAdjuvant radiotherapy

The Central and Eastern European Gynecologic Oncology Group514 participants1 site · CzechiaCompletes Dec 2029

Compare CT.gov Full analysis →

Recruiting

D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC

Phase 3NSCLC (Non-small Cell Lung Cancer)

D-BACE in combination with chemotherapy and karelizumab

Guangdong Provincial People's Hospital70 participants1 site · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Phase 1Phase 2Locally Advanced Breast CancerUnresectable Breast CarcinomaMetastatic Breast Cancer

BNT323BNT327

BioNTech SE380 participants39 sites · United States, Canada, ChinaCompletes May 2028

Compare CT.gov Full analysis →

1–15 of 6,266